Exposure-Response Analyses for Efficacy (SVR12) for the Direct Acting Antiviral Regimen of Paritaprevir/r, Ombitasvir with Dasabuvir ± Ribavirin in Subjects with HCV Genotype 1 Infection

Conference Reports for NaTaP

EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria april 22-26


Exposure-Response Analyses for Efficacy (SVR12) for the Direct Acting Antiviral Regimen of Paritaprevir/r, Ombitasvir with Dasabuvir ± Ribavirin in Subjects with HCV Genotype 1 Infection

	Reported by Jules Levin EASL 2015 April 22-26 Vienna Austria Amit Khatri*1, Sven Mensing2, Thomas Podsadecki3, Walid Awni1, Rajeev Menon1, Sandeep Dutta1 1Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, United States; 2Clinical Pharmacology and Pharmacometrics, AbbVie, Ludwigshafen, Germany; 3Infectious Disease, GPRD, AbbVie, North Chicago, United States